28 ago 2016 ano - FDA announced required class-wide changes to drug labeling to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system depressant drugs called benzodiazepines. Among the changes, the FDA is requiring boxed warnings and Medication Guides.
Adicionado na linha do tempo:
Data:
28 ago 2016 ano
Agora
~ 9 years and 2 months ago